Identification of a novel cis-element that regulates alternative splicing of Bcl-x pre-mRNA

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 467-472

  Lee, Jaehoon ^a   Zhou, Jianhua ^b   Zheng, Xuexiu ^a   Cho, Sunghee ^a   Moon, Heegyum ^a   Loh, Tiing Jen ^a   Jo, Kyungjin ^a   Shen, Haihong ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b NANTONG UNIVERSITY   (China)

Author keywords

Alternative splicing; Apoptosis; Bcl x; Exon inclusion; Exon skipping; Pre mRNA splicing

Indexed keywords

PROTEIN BCL X; PROTEIN BCL XL; PROTEIN BCL XS; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CELL SURVIVAL; EXON; EXON SKIPPING; GENE DELETION; GENE SEQUENCE; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; BASE SEQUENCE; BCL-X PROTEIN; EXONS; HELA CELLS; HUMANS; REGULATORY ELEMENTS, TRANSCRIPTIONAL; RNA PRECURSORS; SEQUENCE ANALYSIS, DNA;

EID: 84862805837     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.029     Document Type: Article

References (39)

1. Li Q., Lee J.A., Black D.L. Neuronal regulation of alternative pre-mRNA splicing. Nat. Rev. Neurosci. 2007, 8:819-831.
2. Saltzman A.L., Pan Q., Blencowe B.J. Regulation of alternative splicing by the core spliceosomal machinery. Genes Dev. 2011, 25:373-384.
3. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72:291-336.
4. Maniatis T., Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 2002, 418:236-243.
5. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40:1413-1415.
6. Wahl M.C., Will C.L., Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009, 136:701-718.
7. Lopez A.J. Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Annu. Rev. Genet. 1998, 32:279-305.
8. Shen H., Kan J.L., Ghigna C., Biamonti G., Green M.R. A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2. RNA 2004, 10:787-794.
9. Rothrock C., Cannon B., Hahm B., Lynch K.W. A conserved signal-responsive sequence mediates activation-induced alternative splicing of CD45. Mol. Cell 2003, 12:1317-1324.
10. Matlin A.J., Clark F., Smith C.W. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6:386-398.
11. Sanford J.R., Ellis J., Caceres J.F. Multiple roles of arginine/serine-rich splicing factors in RNA processing. Biochem. Soc. Trans. 2005, 33:443-446.
12. Graveley B.R., Maniatis T. Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol. Cell 1998, 1:765-771.
13. Graveley B.R. Sorting out the complexity of SR protein functions. RNA 2000, 6:1197-1211.
14. Del Gatto-Konczak F., Olive M., Gesnel M.C., Breathnach R. HnRNP A1 recruited to an exon in vivo can function as an exon splicing silencer. Mol. Cell Biol. 1999, 19:251-260.
15. Dreyfuss G., Kim V.N., Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 2002, 3:195-205.
16. Cooper T.A., Mattox W. The regulation of splice-site selection, and its role in human disease. Am. J. Hum. Genet. 1997, 61:259-266.
17. Lorson C.L., Hahnen E., Androphy E.J., Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 1999, 96:6307-6311.
18. McKenna S.L., McGowan A.J., Cotter T.G. Molecular mechanisms of programmed cell death. Adv. Biochem. Eng. Biotechnol. 1998, 62:1-31.
19. Leist M., Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. 2001, 2:589-598.
20. Fadeel B., Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J. Intern. Med. 2005, 258:479-517.
21. Schwerk C., Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol. Cell 2005, 19:1-13.
22. David C.J., Manley J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010, 24:2343-2364.
23. Chipuk J.E., Moldoveanu T., Llambi F., Parsons M.J., Green D.R. The BCL-2 family reunion. Mol. Cell 2010, 37:299-310.
24. Akgul C., Moulding D.A., Edwards S.W. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol. Life Sci. 2004, 61:2189-2199.
25. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000, 19:6627-6631.
26. Mercatante D.R., Bortner C.D., Cidlowski J.A., Kole R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J. Biol. Chem. 2001, 276:16411-16417.
27. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G., Thompson C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608.
28. Boon-Unge K., Yu Q., Zou T., Zhou A., Govitrapong P., Zhou J. Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chem. Biol. 2007, 14:1386-1392.
29. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 1997, 3:614-620.
30. Lebedeva I., Rando R., Ojwang J., Cossum P., Stein C.A. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 2000, 60:6052-6060.
31. Watanabe J., Kushihata F., Honda K., Mominoki K., Matsuda S., Kobayashi N. Bcl-xL overexpression in human hepatocellular carcinoma. Int. J. Oncol. 2002, 21:515-519.
32. Espana L., Fernandez Y., Rubio N., Torregrosa A., Blanco J., Sierra A. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res. Treat. 2004, 87:33-44.
33. Shkreta L., Michelle L., Toutant J., Tremblay M.L., Chabot B. The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 2011, 286:331-340.
34. Clarke M.F., Apel I.J., Benedict M.A., Eipers P.G., Sumantran V., Gonzalez-Garcia M., Doedens M., Fukunaga N., Davidson B., Dick J.E., Minn A.J., Boise L.H., Thompson C.B., Wicha M., Nunez G. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc. Natl. Acad. Sci. USA 1995, 92:11024-11028.
35. Sumantran V.N., Ealovega M.W., Nunez G., Clarke M.F., Wicha M.S. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 1995, 55:2507-2510.
36. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
37. Kim K. Silencing Bcl-X(L) in cancer therapy. Cancer Biol. Ther. 2005, 4:398-399.
38. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003, 31:3406-3415.
39. Kar A., Fushimi K., Zhou X., Ray P., Shi C., Chen X., Liu Z., Chen S., Wu J.Y. RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site. Mol. Cell Biol. 2011, 31:1812-1821.